2025 Q3 -tulosraportti
84 päivää sitten
‧23 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 317
Myynti
Määrä
7 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 500 | - | - | ||
| 1 000 | - | - | ||
| 306 | - | - | ||
| 185 | - | - | ||
| 2 303 | - | - |
Ylin
0,992VWAP
Alin
0,97VaihtoMäärä
0,2 174 342
VWAP
Ylin
0,992Alin
0,97VaihtoMäärä
0,2 174 342
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 174 342 | 174 342 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 174 342 | 174 342 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 | ||
2024 Q3 -tulosraportti 14.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenA brief description of Klaus Juhl Wulff's CV and what main task will rest on his shoulders By Michael FriisHead of Equities 09.02.2026, 08.52 BioPorto BioPorto can this morning announce that they have appointed Klaus Juhl Wulff as new EVP and CFO with commencement no later than May 1, 2026. Klaus Juhl Wulff will simultaneously join the executive management. He comes from a position as CFO at AquaPorin and has more than 20 years of experience within finance, operations, M&A, and capital markets. As part of his area of responsibility, he will get the strategic responsibility for supply chain with the aim of supporting the expected high growth going forward. The Management.
·2 päivää sittenThe stock expert Lars Hytting from Artha Kapitalforvaltning has today been interviewed by Børsen about the upcoming stock game where he "buys" big time into Bioporto......I am aware that it is for the stock game but I still think he has some interesting short-term and long-term comments about Bioporto and where the company has gotten to now :(And which I strongly agree with ) The first stock that Hytting has chosen to include in the stock game is the Danish biotech company Bioporto. A risky stock, which he assesses can quickly turn around. The stock has fallen 35 pct. in the past year, and the company is currently awaiting approval of a product from the American Food and Drug Administration (FDA). Hytting explains that even if the approval doesn't come through while the stock game is ongoing, even small news about the company could potentially send the stock price soaring. “It's a stock that has been completely beaten down, so if, for example, there's an announcement that they are well on their way with the study, the stock could easily rise 10-20 pct., even if nothing major actually happens,” he says. “It's an interesting stock that has experienced big ups and downs, but which is actually in a good place now. They have a good management and a good board and are relentlessly pursuing this FDA approval. So it's a stock that could actually also be interesting in the long run,” he continues.·13 t sittenI can in no way recommend it, for this could easily end up as a new First North cadaver, but it would probably have been better if the tip for the game had chosen Stenocare. Small, illiquid and with large fluctuations, and then it has a fan base that is probably under construction and that has not taken a beating in 15 years.- ·2 päivää sittenNominally, I have quite a lot of shares in the company. In terms of value, it's, to say the least, not much. But, strictly speaking, they have exclusively lived off the shareholders' money for decades. I'm staying in it, though, and letting it be my lottery ticket. Although I'm starting to believe that the chance for a good win is greater in Lotto than with Bioporto 😅·2 päivää sittenMy stance on the current team, to drive BP forward after PME, is that they are competent people for this job, therefore I have bought up continuously, after PME handed over the reins to CB. In other words, I look at what resources are available to drive the company into the future, and not at what happened in the past, when PME had the reins. I am sure that CB has chosen the right person to be his wingman.
·2 päivää sitten3D You also wrote that in 2024, and again in 2025 and now in 2026. I have probably overlooked your posts from previous years - while PME was in charge.... - ·2 päivää sittenBioporto appoints new CFO today at 08:22 ∙ MarketWire BioPorto Biotechnology company Bioporto has appointed Klaus Juhl Wulff as new CFO and member of the executive management from no later than 1 May 2026. This is stated in a company announcement Monday morning. Klaus Juhl Wulff comes from the role as CFO at bankrupt Aquaporin. Klaus brings a strong CFO track record and relevant leadership experience and will be a strong addition to the management team. As part of his CFO duties, Klaus will take strategic lead in our supply chain to enable the expected high growth as we develop. His interest in joining Bioporto with his experience shows strong commitment and belief in our journey ahead, and I am excited to welcome Klaus to Bioporto, says Carsten Buhl, CEO at Bioporto.
- ·6.2.Watch or rewatch webinar regarding preliminary financial statements Q4 2025 https://www.inderes.dk/videos/bioporto-praesentation-af-forelobige-2025-resultater-samt-2026-guidance
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
84 päivää sitten
‧23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenA brief description of Klaus Juhl Wulff's CV and what main task will rest on his shoulders By Michael FriisHead of Equities 09.02.2026, 08.52 BioPorto BioPorto can this morning announce that they have appointed Klaus Juhl Wulff as new EVP and CFO with commencement no later than May 1, 2026. Klaus Juhl Wulff will simultaneously join the executive management. He comes from a position as CFO at AquaPorin and has more than 20 years of experience within finance, operations, M&A, and capital markets. As part of his area of responsibility, he will get the strategic responsibility for supply chain with the aim of supporting the expected high growth going forward. The Management.
- ·2 päivää sittenThe stock expert Lars Hytting from Artha Kapitalforvaltning has today been interviewed by Børsen about the upcoming stock game where he "buys" big time into Bioporto......I am aware that it is for the stock game but I still think he has some interesting short-term and long-term comments about Bioporto and where the company has gotten to now :(And which I strongly agree with ) The first stock that Hytting has chosen to include in the stock game is the Danish biotech company Bioporto. A risky stock, which he assesses can quickly turn around. The stock has fallen 35 pct. in the past year, and the company is currently awaiting approval of a product from the American Food and Drug Administration (FDA). Hytting explains that even if the approval doesn't come through while the stock game is ongoing, even small news about the company could potentially send the stock price soaring. “It's a stock that has been completely beaten down, so if, for example, there's an announcement that they are well on their way with the study, the stock could easily rise 10-20 pct., even if nothing major actually happens,” he says. “It's an interesting stock that has experienced big ups and downs, but which is actually in a good place now. They have a good management and a good board and are relentlessly pursuing this FDA approval. So it's a stock that could actually also be interesting in the long run,” he continues.·13 t sittenI can in no way recommend it, for this could easily end up as a new First North cadaver, but it would probably have been better if the tip for the game had chosen Stenocare. Small, illiquid and with large fluctuations, and then it has a fan base that is probably under construction and that has not taken a beating in 15 years.
- ·2 päivää sittenNominally, I have quite a lot of shares in the company. In terms of value, it's, to say the least, not much. But, strictly speaking, they have exclusively lived off the shareholders' money for decades. I'm staying in it, though, and letting it be my lottery ticket. Although I'm starting to believe that the chance for a good win is greater in Lotto than with Bioporto 😅·2 päivää sittenMy stance on the current team, to drive BP forward after PME, is that they are competent people for this job, therefore I have bought up continuously, after PME handed over the reins to CB. In other words, I look at what resources are available to drive the company into the future, and not at what happened in the past, when PME had the reins. I am sure that CB has chosen the right person to be his wingman.·2 päivää sitten3D You also wrote that in 2024, and again in 2025 and now in 2026. I have probably overlooked your posts from previous years - while PME was in charge....
- ·2 päivää sittenBioporto appoints new CFO today at 08:22 ∙ MarketWire BioPorto Biotechnology company Bioporto has appointed Klaus Juhl Wulff as new CFO and member of the executive management from no later than 1 May 2026. This is stated in a company announcement Monday morning. Klaus Juhl Wulff comes from the role as CFO at bankrupt Aquaporin. Klaus brings a strong CFO track record and relevant leadership experience and will be a strong addition to the management team. As part of his CFO duties, Klaus will take strategic lead in our supply chain to enable the expected high growth as we develop. His interest in joining Bioporto with his experience shows strong commitment and belief in our journey ahead, and I am excited to welcome Klaus to Bioporto, says Carsten Buhl, CEO at Bioporto.
- ·6.2.Watch or rewatch webinar regarding preliminary financial statements Q4 2025 https://www.inderes.dk/videos/bioporto-praesentation-af-forelobige-2025-resultater-samt-2026-guidance
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 317
Myynti
Määrä
7 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 500 | - | - | ||
| 1 000 | - | - | ||
| 306 | - | - | ||
| 185 | - | - | ||
| 2 303 | - | - |
Ylin
0,992VWAP
Alin
0,97VaihtoMäärä
0,2 174 342
VWAP
Ylin
0,992Alin
0,97VaihtoMäärä
0,2 174 342
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 174 342 | 174 342 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 174 342 | 174 342 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 | ||
2024 Q3 -tulosraportti 14.11.2024 |
2025 Q3 -tulosraportti
84 päivää sitten
‧23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 | ||
2024 Q3 -tulosraportti 14.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenA brief description of Klaus Juhl Wulff's CV and what main task will rest on his shoulders By Michael FriisHead of Equities 09.02.2026, 08.52 BioPorto BioPorto can this morning announce that they have appointed Klaus Juhl Wulff as new EVP and CFO with commencement no later than May 1, 2026. Klaus Juhl Wulff will simultaneously join the executive management. He comes from a position as CFO at AquaPorin and has more than 20 years of experience within finance, operations, M&A, and capital markets. As part of his area of responsibility, he will get the strategic responsibility for supply chain with the aim of supporting the expected high growth going forward. The Management.
- ·2 päivää sittenThe stock expert Lars Hytting from Artha Kapitalforvaltning has today been interviewed by Børsen about the upcoming stock game where he "buys" big time into Bioporto......I am aware that it is for the stock game but I still think he has some interesting short-term and long-term comments about Bioporto and where the company has gotten to now :(And which I strongly agree with ) The first stock that Hytting has chosen to include in the stock game is the Danish biotech company Bioporto. A risky stock, which he assesses can quickly turn around. The stock has fallen 35 pct. in the past year, and the company is currently awaiting approval of a product from the American Food and Drug Administration (FDA). Hytting explains that even if the approval doesn't come through while the stock game is ongoing, even small news about the company could potentially send the stock price soaring. “It's a stock that has been completely beaten down, so if, for example, there's an announcement that they are well on their way with the study, the stock could easily rise 10-20 pct., even if nothing major actually happens,” he says. “It's an interesting stock that has experienced big ups and downs, but which is actually in a good place now. They have a good management and a good board and are relentlessly pursuing this FDA approval. So it's a stock that could actually also be interesting in the long run,” he continues.·13 t sittenI can in no way recommend it, for this could easily end up as a new First North cadaver, but it would probably have been better if the tip for the game had chosen Stenocare. Small, illiquid and with large fluctuations, and then it has a fan base that is probably under construction and that has not taken a beating in 15 years.
- ·2 päivää sittenNominally, I have quite a lot of shares in the company. In terms of value, it's, to say the least, not much. But, strictly speaking, they have exclusively lived off the shareholders' money for decades. I'm staying in it, though, and letting it be my lottery ticket. Although I'm starting to believe that the chance for a good win is greater in Lotto than with Bioporto 😅·2 päivää sittenMy stance on the current team, to drive BP forward after PME, is that they are competent people for this job, therefore I have bought up continuously, after PME handed over the reins to CB. In other words, I look at what resources are available to drive the company into the future, and not at what happened in the past, when PME had the reins. I am sure that CB has chosen the right person to be his wingman.·2 päivää sitten3D You also wrote that in 2024, and again in 2025 and now in 2026. I have probably overlooked your posts from previous years - while PME was in charge....
- ·2 päivää sittenBioporto appoints new CFO today at 08:22 ∙ MarketWire BioPorto Biotechnology company Bioporto has appointed Klaus Juhl Wulff as new CFO and member of the executive management from no later than 1 May 2026. This is stated in a company announcement Monday morning. Klaus Juhl Wulff comes from the role as CFO at bankrupt Aquaporin. Klaus brings a strong CFO track record and relevant leadership experience and will be a strong addition to the management team. As part of his CFO duties, Klaus will take strategic lead in our supply chain to enable the expected high growth as we develop. His interest in joining Bioporto with his experience shows strong commitment and belief in our journey ahead, and I am excited to welcome Klaus to Bioporto, says Carsten Buhl, CEO at Bioporto.
- ·6.2.Watch or rewatch webinar regarding preliminary financial statements Q4 2025 https://www.inderes.dk/videos/bioporto-praesentation-af-forelobige-2025-resultater-samt-2026-guidance
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 317
Myynti
Määrä
7 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 500 | - | - | ||
| 1 000 | - | - | ||
| 306 | - | - | ||
| 185 | - | - | ||
| 2 303 | - | - |
Ylin
0,992VWAP
Alin
0,97VaihtoMäärä
0,2 174 342
VWAP
Ylin
0,992Alin
0,97VaihtoMäärä
0,2 174 342
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 174 342 | 174 342 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 174 342 | 174 342 | 0 | 0 |